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Abstract
The molecular basis for the exquisite sensitivity of testicular germ cell tumours of
adolescents and adults (TGCTs), ie seminomas and non-seminomatous germ cell tumours, to
chemo/radiotherapy has not been fully clarified so far. It has been suggested that it may be
dependent on factors involved in the regulation of apoptosis. Seladin-1 is a multi-functional
protein involved in various biological processes, including apoptosis. The aim of our study
was to assess the expression of seladin-1 in different histological types of TGCTs, known to
have varying treatment sensitivity, in order to establish whether this protein may influence
cisplatin responsiveness in vitro. Seladin-1 expression levels, both at the mRNA and at the
protein level, were higher in the adjacent normal parenchyma than in the pathological
counterparts. In tumoural tissues, the level of expression differed among TGCT histological
types. The highest tumour-expression level was found in teratoma, whereas the lowest
was detected in seminoma, corresponding to the different chemo/and radiosensitivities of
these tumour types. In common with other cancers, in TGCT-derived cell lines seladin-1
showed anti-apoptotic properties through inhibition of caspase-3 activation. We confirmed
our results using a non-seminomatous cell line model (NT2) before and after differentiation
with retinoic acid. Significantly higher seladin-1 expression was observed in the differentiated
derivatives (teratoma) and an inverse relationship was found between seladin-1 expression
and the amount of cleaved caspase-3. Seladin-1 silencing or overexpression in this cell
line supports involvement of seladin-1 in cisplatin responsiveness. Seladin-1 silencing was
associated with greater cisplatin responsiveness demonstrated by decreased cell viability
and increased expression of apoptotic markers. In contrast, overexpression of seladin-1 was
associated with a higher survival rate and a clear anti-apoptotic effect. In conclusion, we
have demonstrated for the first time an important role for seladin-1 in the biology of TGCTs
and provided new insights into cisplatin responsiveness of these tumours.
Copyright  2009 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
Keywords: TGCT; testicular cancer; seladin-1; cisplatin; male infertility; apoptosis
Introduction
TGCTs (testicular germ cell tumours of adolescents
and adults) are the most frequently occurring tumours
in young men, with a peak of incidence between the
ages of 15 and 34 years. They account for up to 60%
of all malignancies diagnosed at this age, with an
incidence of 6–7 per 100 000 men. Despite a high
cure rate, TGCTs represent the most frequent cause of
death from solid tumours in this age group and show
an annual increase in incidence of 2–5% [1]. TGCTs
are a heterogeneous group of neoplasms derived from
the germ cell lineage [2–4] and usually occurring
within the gonads. Based on histological, biochem-
ical, and clinical characteristics, TGCTs are divided
into seminomas and non-seminomatous tumours [5].
Seminomas are composed of uniform tumour cells,
resembling primordial germ cells/gonocytes [6,7].
In contrast, non-seminomatous TGCTs may contain
one or more histological subtypes, representing vari-
ous differentiation lineages and stages of embryonic
development. Embryonal carcinoma cells form the
stem cell component and are able to differentiate
towards extra-embryonic tissues (yolk-sac carcinoma
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and choriocarcinoma) or embryonic tissues (immature
and mature teratoma) [8,9]. The rapid growth and pro-
gression of TGCTs cause early lymph node metastases
and/or distant metastases. About 25% of seminoma
patients [10] and up to 60% of non-seminomatous
patients have metastatic disease at the time of diag-
nosis [11–13].
Seminomas are radio- and chemo-sensitive tumours,
virtually completely curable at each stage [14]. Non-
seminomatous TGCTs are usually treated with surgery
and chemotherapy, with varying cure rates depend-
ing on the disease stage and histological compo-
sition [15]. The cure rate is close to 99% in the
early stages, whereas it may be as low as 50% in
advanced disease stages with a poor prognosis. There-
fore, despite the fact of successful treatment of TGCTs
with cisplatinum-based combination chemotherapy,
10–20% of patients diagnosed with metastatic disease
will not achieve a sustained complete remission after
initial treatment, due either to incomplete response or
to tumour relapse [16,17].
The molecular basis for the exquisite sensitivity of
TGCTs to cisplatin is not yet known and a number of
hypotheses have been suggested [18]. Among them,
an attractive hypothesis is that TGCTs are so readily
curable because of a low threshold for induction
of apoptosis. However, studies published so far on
this topic have yielded contradictory results [18]
and encourage further research in this direction. For
example, the expression of the anti-apoptotic protein
seladin-1 (selective Alzheimer’s disease indicator-1) in
the different histological types of TGCT is unknown
so far, but might be of interest.
Seladin-1, encoding 3β-hydroxysterol 24-red-
uctase (DHCR24) [19], catalyses the reduction of
the 24 double bond in desmosterol to produce
cholesterol, which is down-regulated in brain regions
affected by Alzheimer’s disease [20]. Expression of
seladin-1 is widespread in human tissues [20], with
the highest levels being observed in the adrenal gland,
prostate, lung, and fetal liver. In addition, seladin-1 is
expressed in the brain and in various endocrine organs,
such as adrenal cortex [21–24], testis, and ovary
[20,22,25]. Seladin-1 effectively inhibits caspase-3
activity, a key mediator of apoptosis, and protects
neuronal cells from apoptotic death [20,26,27], thus
suggesting its involvement in the regulation of cell
survival and death.
Seladin-1 expression has been investigated in dif-
ferent tumours including adrenal gland, prostate, ovar-
ian, and pituitary tumours, and melanomas [21,23–25,
28–30]. In some of these tumours seladin-1 is over-
expressed, whereas in others it is reduced compared
with the corresponding normal tissue. A potential
role for seladin-1 in the metastatic process has been
observed in prostate cancer [29,30] and in melanoma
[28]. High levels of seladin-1 in prostate cancer
tissues are associated with local invasiveness and dis-
ease recurrence [30], whereas in melanoma seladin-
1 expression is up-regulated in metastases compared
with primary tumours, thus suggesting a role for this
protein in tumour progression.
Seladin-1 is highly expressed in the normal testis,
probably due to the presence of steroid-producing cells
[20]. However, it is unknown whether seladin-1 plays
any role in germ cells or if it is involved in the
pathogenesis of germ cell-derived tumours. In order
to obtain further insights into the biology of TGCTs,
we recorded the expression pattern of seladin-1 in
different TGCTs and in a related cell line model (NT2).
Furthermore, we investigated the role of this protein in
cisplatin responsiveness, by modulating its expression
levels in this cell line.
Materials and methods
Patients
Thirty-four patients undergoing surgery for TGCTs
(n = 8 seminomas, n = 4 teratomas, n = 4 embryonal
carcinomas, n = 4 choriocarcinomas, n = 4 mixed
embryonal carcinomas and seminomas, n = 6 mixed
embryonal carcinomas and teratomas, and n = 4
mixed embryonal carcinomas and choriocarcinomas)
were included in this study. From each patient, tissue
from the tumour and from the tumour-free, normal
parenchyma was immediately frozen in liquid nitro-
gen and stored at −80 ◦C, pending RNA and pro-
tein extraction. It is worth noting that the tumour-
free parenchyma was not atrophic. However, we can-
not exclude differences in the number of intratubular
germ cells among different subjects. Therefore, the
term ‘normality’ as used here indicates the absence
of tumour or the precursor lesion, and not necessarily
the presence of normal spermatogenesis.
Cell culture and differentiation
NTERA-2 cl.D1 [NT2/D1] or NT2 cells, a pluripo-
tent human embryonal carcinoma cell line, was kindly
provided by Dr LHJ Looijenga. NT2 cells were
cultured in monolayer as described previously in
DMEM (4.5 g/l glucose, sodium pyruvate, and glu-
tamax) supplemented with 10% FBS (Hyclone), peni-
cillin/streptomycin (Sigma-Aldrich). NT2 cells differ-
entiate upon treatment with all-trans retinoic acid
(RA) and begin to show a neuronal morphology after
4 weeks of 10 µM RA treatment [31].
Induction of apoptosis by cisplatin
NT2 cells were treated with 10 µM cisplatin (Pfizer
srl) for 2 h at 37 ◦C prior to harvesting 24–48 h later,
according to Muller et al [32,33].
MTS-tetrazolium salt assay
The Promega CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay was used to measure the cyto-
toxicity of cisplatin by determining the number of
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viable cells in culture. The MTS [3-(4,5-dimethyl-
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
phophenyl)-2H-tetrazolium] assay is based on the
ability of viable cells to convert a soluble tetra-
zolium salt into a formazan product. After exposure,
the MTS/PMS reagent was added and cell cultures
were incubated at 37 ◦C for 30 min. At the end of
the incubation period, absorbance was recorded at
490 nm (Microplate Reader, Bio-Rad). The results
were expressed in terms of mean ± SE viable cells
per well in three different experiments.
Small interfering RNA (siRNA) inhibition
of seladin-1 expression
siRNAs targeting seladin-1 and negative control
(siCONTROL non-targeting) were as previously des-
cribed [34]. NT2 cells were grown to confluence
between 70% and 80%, and washed with pre-warmed
(37 ◦C) PBS. siRNAs targeting seladin-1 or control
siRNAs (100 nM) were mixed with Lipofectamine
2000 (Invitrogen srl, Milan, Italy) and administered to
the cells (24 h), following the manufacturer’s instruc-
tions. For seladin-1 expression studies, treatment with
cisplatin (10 µM) was performed for an additional
24–48 h after silencing.
Seladin-1 overexpression
A cDNA sequence of 1657 bp containing the entire
ORF of seladin-1 was obtained by RT-PCR per-
formed on total RNA derived from human fetal neu-
roepithelial cells (FNCs), which express this protein
[35], using the forward primer 5′-agtgacaggaggcgcgaa-
3′ and the reverse primer 5′-agtgaagggaagatgcctga-3′.
This sequence was cloned in pcDNA4/HisMax vector
(Invitrogen, Carlsbad, CA, USA), a plasmid vector for
high-level expression in mammalian cells of seladin-1
as a fusion to the N-terminal poly-histidine tag. This
construct was sequenced and designated pcDNA-Sel.
Cells were transfected with pcDNA-Sel using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA, USA) on
cells plated at 90% confluence in DMEM supple-
mented with 10% FBS without antibiotics. Forty-eight
hours after transfection, the cells were selected with
100 µg/ml zeocin for a total of 5 weeks. Moreover,
NT2 cells were stably transfected with the empty vec-
tor pcDNA for control.
RNA extraction and quantitative real-time
RT-PCR
Total RNA was obtained from tissues and NT2 cells
using an RNeasy mini kit (Qiagen Inc, Valencia, CA,
USA). Total RNA (400 ng) was reverse-transcribed
in 80 µl of final volume using the TaqMan Universal
Master Mix (Applied Biosystems). The profile of the
one-step, reverse-transcription reaction was 10 min at
25 ◦C, 30 min at 48 ◦C, and 5 min at 95 ◦C. TaqMan
primers, probe, and thermal cycling conditions for
seladin-1 [23] and for OCT4 and NANOG [36] were
as previously described.
Protein extraction and western blot analysis
Total proteins were extracted from 34 testis tumours
and from normal testicular samples. Frozen tissues
were ground in liquid nitrogen, re-suspended in lysis
buffer [20 mM Tris–HCl (pH 7.4), 150 mM NaCl,
0.2 mM EDTA, 1% Triton X-100] containing protease
inhibitors (1 mM AEBSF, 0.3 µM aprotinin, 10 µg/ml
pepstatin; Sigma, Milan, Italy), and homogenized by
potter. Total proteins were extracted from NT2 cells
before and after differentiation and/or cisplatin treat-
ment. The cells were lysed for 30 min at 4 ◦C in
lysis buffer and centrifuged at 12 000 g for 3 min
at 4 ◦C; the supernatant was used for western blot
analysis, after protein quantification by Biorad protein
assay (Bradford). For western blot, a rabbit polyclonal
anti-seladin-1 antibody (1 : 1000), specific for the N-
terminal of 60 kD seladin-1 protein (Sigma, Italy), and
three rabbit polyclonal antibodies specific for cleaved
caspase-3 (Asp175) (Cell Signaling Technology, Bev-
erly, MA, USA), PARP, and neuronal enolase (Santa
Cruz Biotechnology, Inc) were used.
Immunohistochemistry
Immunohistochemical analysis was performed on
3 µm thick sections from formalin-fixed and paraffin-
embedded specimens. All sections were deparaffinized
in xylene and hydrated with graded ethanol. To block
endogenous peroxidase activity, slides were treated
with 3.0% hydrogen peroxidase in distilled water for
5 min. Antigen retrieval was routinely performed by
immersing the sections in 0.01 M Tris/0.01 M EGTA
(pH 8.0) buffer at high temperature in a pressure
cooker. To block endogenous biotin (Vector Blocking
Agent Kit SP 2001), the sections were treated with
avidin and biotin solutions and subsequently stained
with a polyclonal antibody against seladin-1 (Sigma)
at 1 : 400 dilution in PBS/BSA 0. 22% and incubated
for 2 h at room temperature.
Primary antibody bound to antigen was detected
with a standard (avidin) streptavidin–biotin–per-
oxidase technique and visualized with 3,3′-diamino-
benzidine as a chromogen. Nuclei were counterstained
with Mayer’s haematoxylin. Sections of an adrenal
cortical adenoma, showing strong immunopositivity
for seladin-1, were used as positive controls, whereas
negative controls were performed by replacing the pri-
mary antibody with a non-immune serum at the same
concentration. Control sections were treated in parallel
with the samples under investigation in the same run.
Results
Seladin-1 tissue expression pattern
We measured the mRNA expression level of seladin-
1 by quantitative real-time RT-PCR in 20 TGCTs of
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Figure 1. Seladin-1 expression and apoptosis in TGCTs. (a) Comparison of seladin-1 mRNA levels in normal testis versus TGCTs,
determined by real-time RT-PCR. Note the significantly lower expression level in the tumours compared with the normal tissue.
(b) Comparison of seladin-1 mRNA levels in teratomas versus other histological types of TGCTs. Note the significantly higher
level of expression in the first compared with the second. (c) Western blot analysis of seladin-1 and cleaved caspase-3 in TGCTs
and in matched adjacent normal testicular parenchyma. β-Actin was used as a loading control. The histologies as well as the
size of the proteins are indicated. TGCTs = testicular germ cell tumours; S = seminoma; EC = embryonal carcinoma; CC =
choriocarcioma; T = teratoma; Tm = tumour part; N = normal tissue
different histological types and in the adjacent normal
parenchyma. The level of seladin-1 expression was
significantly reduced in TGCTs compared with the
‘normal’ part of the testis (Figure 1a, p = 0.029).
The lowest expression level was found in seminomas,
followed by embryonal carcinomas and teratomas.
The expression level of seladin-1 was significantly
higher in teratomas than in all the other histological
types (p = 0.021) (Figure 1b). Western blot analysis
for seladin-1 was performed in 34 TGCTs and in their
adjacent normal parenchyma. The amount of protein
was in agreement with the corresponding amount of
mRNA (Figure 1c).
Immunohistochemistry was performed on a tis-
sue microarray containing different TGCT histotypes.
Both carcinoma in situ (CIS) and seminomas showed
weak positive staining for seladin-1, whereas chori-
ocarcinomas and teratomas showed strong positiv-
ity, thus confirming the mRNA and western blot
data (Figure 2). Twenty-four primary spermatocytic
seminomas were also stained and were all posi-
tive for seladin-1 (see Figure 2f). In normal testis,
strong immunopositivity was observed in Leydig cells,
whereas no staining in Sertoli cells and a weak sig-
nal were found in spermatogonia and in later stages
of spermatogenesis (Figure 3). Analysis of fetal testis
at different stages (16 and 36 weeks) of development
showed no staining in the early stage (similarly to CIS
and seminomas), whereas a high degree of expres-
sion was observed in the germinal components at the
later stage. Immunostaining for seladin-1 was present
in Leydig cells in all cases (Figure 3).
Seladin-1 expression in the NT2 cell line
In order to confirm the data obtained in testis tissue
samples, seladin-1 expression was analysed in the NT2
cell line before and after differentiation induced by
RA. Differentiation was confirmed by an increase of
γ -enolase (a specific neuronal marker) protein levels
and a significant decrease of OCT4 and NANOG (spe-
cific stem cell markers) mRNA expression compared
with the undifferentiated cells (OCT4, p = 0.039;
NANOG, p = 0.023) (Supporting information, Sup-
plementary Figure 1). Seladin-1 mRNA increased sig-
nificantly (p = 0.017) after 28 days of RA treatment
(Figure 4a). The expression of seladin-1 at the protein
level followed the same pattern (Figure 4b).
Seladin 1 expression and apoptosis
Since seladin-1 is known to inhibit the activation
of caspase-3, which is a key mediator of apoptosis,
we analysed the amount of cleaved caspase-3 in
the same set of TGCTs and in the NT2 cell line
under the various growth conditions. The expression
level of cleaved caspase-3 showed an opposite pattern
to that of seladin-1 in tissues (Figure 1c) and cells
(Figure 4b), supporting the idea of an anti-apoptotic
role for this protein also in TGCTs. Similarly, the
J Pathol 2009; 219: 491–500 DOI: 10.1002/path
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Figure 2. Seladin-1 protein expression evaluated by immuno-
histochemistry on tissue sections of primary TGCTs and normal
testicular parenchyma. Representative examples are shown of
(a) testicular parenchyma containing a seminiferous tubule with
carcinoma in situ (left part of the image), embryonal carcinoma
(right part of the image), and Leydig cells (dark cells between
the seminiferous tubules); (b) seminoma; (c) choriocarcinoma;
(d, e) teratoma containing predominantly epithelial structures;
and (f) spermatocytic seminoma showing more intense staining
than seminoma
Figure 3. Seladin-1 protein expression evaluated by immuno-
histochemistry on tissue sections: (a) normal adult testis show-
ing strong staining of Leydig cells around seminiferous tubules.
Spermatogonia also show positivity. (b, c) Embryonic testis of
16 weeks of gestation showing again a high level of expression
in Leydig cells, but absence of staining within the seminiferous
tubules. (d) Embryonic testis of 36 weeks of gestation, showing
both staining in the Leydig cells and in germ cells within the
seminiferous tubules
protein expression level of cleaved PARP decreased
in NT2 differentiated cells (Figure 4b) compared with
the undifferentiated cells, confirming an anti-apoptotic
effect.
Seladin-1 expression and sensitivity to cisplatin
NT2 undifferentiated cells
As expected, 24 and 48 h after the treatment of undif-
ferentiated NT2 cells with cisplatin (10 µM, for 2 h
at 37 ◦C), we observed an induction of apoptosis
(increased cleaved PARP and caspase-3; Figure 5a)
and a significant reduction of cell viability (Supporting
information, Supplementary Figure 2). Conversely,
seladin-1 protein expression showed an inverse trend
and reduced levels were observed both at 24 h and at
48 h after cisplatin treatment (Figure 5a).
NT2 differentiated cells
In accordance with clinical observations, cisplatin
treatment in differentiated NT2 cells did not lead to
induction of apoptosis, indicating that differentiated
cells are less sensitive to this drug (Figure 5b). Also
in these cells, seladin-1 expression decreased after cis-
platin treatment, although the residual level of expres-
sion after cisplatin remained higher compared with the
undifferentiated cells (Figure 5b). This phenomenon
was also evident at the mRNA expression level (Sup-
porting information, Supplementary Figure 3).
Seladin-1 silencing and overexpression
in undifferentiated NT2 cells
Silencing
Seladin-1 siRNA and control siRNA were transfected
into NT2 by lipofection. Real-time RT-PCR and west-
ern blot analysis showed that the amounts of tran-
script and protein were markedly decreased in NT2
after 24 h from administration of seladin-1 targeting
siRNA (siNT2), but not in cells transfected with con-
trol siRNA (Figure 6a). Similarly, an increased expres-
sion level of cleaved PARP and cleaved caspase-3
(Figure 6b) was observed in siNT2, but not in c-siNT2
treated cells. Moreover, cell viability was significantly
lower 48 h after treatment with cisplatin in siNT2
compared with c-siNT2 (Figure 6c, p = 0.005), indi-
cating the involvement of seladin-1 in the apoptotic
response of these cells to cisplatin.
Overexpression
In undifferentiated NT2 cells overexpressing seladin-1
(NT2Sel-1; Figure 7a), a moderate decrease in cleaved
caspase-3 levels, without any change in cleaved PARP
levels, was observed after cisplatin administration
(Figure 7b). Cell viability in the same conditions
was significantly higher in NT2 cells overexpressing
seladin-1 (NT2Sel-1) than in cells transfected with the
empty vector (NT2pcDNA; Figure 7c), further sup-
porting a role for seladin-1 in cisplatin responsiveness.
Discussion
TGCTs represent a histologically heterogeneous group
of neoplasms derived from the germ cell lineage.
J Pathol 2009; 219: 491–500 DOI: 10.1002/path
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Figure 4. Seladin-1 expression and apoptosis in the TGCT-derived cell line NT2 cells before and after differentiation with retinoic
acid (RA). (a) Real-time RT-PCR quantification of the seladin-1 transcript, showing up-regulation upon differentiation. (b) Western
blot analysis of seladin-1, cleaved caspase-3, and cleaved PARP under both growth conditions, confirming increase of protein as
suggested by mRNA analysis, and decrease of cleaved caspase-3 and cleaved PARP levels in the differentiated cells. β-Actin was
used as a loading control. NT2 = NTERA2 cells; NT2 Diff = NTERA2 cells differentiated with 10 µM retinoic acid for 28 days
Figure 5. Cisplatin treatment in NT2 cells: Western blot analysis of cleaved PARP, cleaved caspase-3, and seladin-1 in the various
growth conditions: (a) undifferentiated and (b) differentiated NT2 cells. Note the difference in cleaved PARP and caspase-3,
associated with changes in seladin-1 protein levels. β-Actin was used as a loading control. cispl = 10 µM cisplatin for 2 h at 37 ◦C
In contrast with the majority of solid tumours, most
TGCTs can be cured by chemotherapy. Understanding
the molecular basis of this particular characteristic
of TGCTs is of relevance, not only to allow better
clinical management of patients with TGCTs, but also
because it may provide new clues for more effective
J Pathol 2009; 219: 491–500 DOI: 10.1002/path
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Figure 6. Seladin-1 silencing in NT2 cells. (a) Real-time RT-PCR and western blot quantification of the seladin-1 transcript and
protein after seladin-1 silencing. NT2 undifferentiated cells were transfected with siRNAs targeting seladin-1 (siNT2) or control
siRNAs (c-siNT2). Note the specific down-regulation, both at the mRNA and at the protein level using the specific siRNA.
(b) Western blot analysis of cleaved PARP and cleaved caspase-3 after seladin-1 silencing in NT2 cells treated with cisplatin. The
seladin-1 silenced cells show increased cleaved PARP and caspase-3 after cisplatin exposure. (c) MTS-tetrazolium salt assay in
NT2, c-siNT2, and siNT2 cells after 48 h exposure to cisplatin. The results are expressed in terms of mean ± SE (standard error)
viable cells per well in three different experiments. Note the specific decrease in viability in the seladin-1 silenced cells
treatment of other solid cancers. It is widely accepted
that there are many factors contributing to the unique
chemosensitivity of TGCTs, including an inability to
detoxify cisplatin and to repair DNA damage, and an
intact apoptotic cascade not disrupted by anti-apoptotic
stimuli [18].
In the present study, we focused on the expression
of seladin-1 in different TGCT histological types and
in a cell line model (NT2), before and after differ-
entiation into teratoma. We also evaluated the role
of seladin-1 in cisplatin responsiveness by silencing
or overexpressing this gene. Seladin-1 was originally
described as a gene with anti-apoptotic activity that is
down-regulated in vulnerable brain regions in patients
affected by Alzheimer’s disease.
Seladin-1 mRNA is ubiquitously expressed in
human adult and fetal tissues, with the exception of
blood cells [20]. In neoplastic tissues and cell lines,
its expression varies and both down- and up-regulation
have been reported, compared with the corresponding
normal counterparts. A high expression level has been
observed in prostate [29,30], liver, lung [20], ovarian
cancer [25], and metastatic melanoma [28], and in cell
lines derived from cerebral tumours and from neurob-
lastoma [26]. Conversely, seladin-1 is down-regulated
in adrenal cancer compared with adenoma and normal
adrenal tissue [23].
Our study shows that seladin-1 gene expression,
both at the mRNA and at the protein level, differs
among different TGCT histotypes and shows the high-
est level in tumour-free normal tissues, regardless of
the adjacent tumour type. This finding is not surprising
if we consider the role of seladin-1 in steroidogene-
sis. Seladin-1 is the enzyme (DHCR24) that converts
desmosterol into cholesterol [19] and is thus a key
enzyme for steroidogenesis. In keeping with this func-
tion, immunohistochemical staining for seladin-1 was
very strong in Leydig cells, which produce the steroid
hormone testosterone. In contrast, no obvious stain-
ing of seladin-1 was identified in Sertoli cells. In
the ovary — another organ which synthesizes steroid
hormones — the normal ovarian tissue showed the
highest expression level when compared with ovarian
epithelial carcinoma and granulosa cell tumours [25].
Besides in Leydig cells, seladin-1 is also expressed
during the early stages of spermatogenesis. This find-
ing appears to be in agreement with the anti-apoptotic
function of this protein. The immunostaining of fetal
testes at different developmental stages is in line with
the up-regulation of seladin-1 during normal germ cell
development in humans. This finding opens up new
perspectives for this gene as a potential candidate gene
for spermatogenesis.
Despite their common cellular origin, different
TGCT histological types show sharp differences
in their biology and the differential expression of
seladin-1 may reflect these differences. The seladin-
1 expression pattern is clearly in accordance with
J Pathol 2009; 219: 491–500 DOI: 10.1002/path
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Figure 7. Seladin-1 overexpression in NT2. (a) Real-time RT-PCR and western blot quantification of seladin-1 in NT2 cells stably
transfected with seladin-1 (NT2Sel-1) or with the empty vector pcDNA as a control (NT2pcDNA). Note the up-regulation of
seladin-1 at the mRNA level. (b) Western blot analysis of cleaved PARP and cleaved caspase-3 in NT2pcDNA and NT2Sel-1 before
and after cisplatin administration to the cells. The seladin-1 overexpressed cells show a moderate decrease in cleaved caspase-3
levels, without any change in cleaved PARP levels. (c) MTS-tetrazolium salt assay in NT2, NT2pcDNA, and NT2Sel-1 48 h after
treatment with cisplatin. The results are expressed in terms of mean ± SE viable cells per well in three different experiments.
Note the specific increase in viability in the seladin-1 overexpressed cells
the different chemo/radiosensitivities of the major his-
totypes. The highest expression level was found in
teratoma, whereas the lowest was in seminoma. The
negligible expression of this anti-apoptotic protein in
seminoma is in agreement with the strong tendency of
this tumour type to undergo apoptosis both in in vitro
cell cultures and following radiotherapy. By contrast,
overexpression of seladin-1 in teratoma reflects the
chemotherapy resistance of this histological type and
is similar to the pattern found in cell lines from
chemoresistant metastatic melanoma [28]. It is inter-
esting to note that spermatocytic seminomas, which
are TGCTs with a separate pathogenesis from semi-
noma, show strong expression of seladin-1. Our find-
ing is in line with previous reports showing important
differences between the set of genes overexpressed
in seminoma compared with spermatocytic seminoma
[37,38]. Genes that are overexpressed in spermato-
cytic seminoma are mainly related to spermatogenesis
(especially those involved in the induction of meio-
sis), whereas seminoma shows up-regulation of genes
involved in stem cell renewal. Our finding provides
further evidence for the hypothesis that spermatocytic
seminoma originates from a later maturation stage than
seminomas.
In TGCTs, as in other cancers, seladin-1 exerts its
anti-apoptotic role through the inhibition of caspase-3
activation. We observed an inverse relationship be-
tween seladin-1 expression and cleaved caspase-3
in both tissue specimens and our cell line model
(NT2 cells). In order to explore further the link
between seladin-1 and chemosensitivity/resistance, we
performed functional studies in NT2 cells following
administration of cisplatin. We observed a modulation
of seladin-1 expression by cisplatin both in undiffer-
entiated (embryonal carinoma) and differentiated (ter-
atoma) cells. In both cell types, cisplatin was able
to down-regulate seladin-1 expression, although this
effect was associated with up-regulation of apoptotic
markers only in undifferentiated cells. The different
behaviours of the two cell types may be explained
by the different baseline expression levels of seladin-
1, which is significantly higher in differentiated cells.
In fact, even if cisplatin treatment is able to reduce
seladin-1 expression in these cells, its level remains
much higher compared with undifferentiated cells. It is
therefore likely that the high residual expression level
of seladin-1 in teratoma cells is able to counteract the
effect of cisplatin.
Our functional studies based on seladin-1 silenc-
ing and overexpression showed clear evidence of
the involvement of seladin-1 in cisplatin responsive-
ness in NT2 cells. Seladin-1 silencing was associated
with a higher responsiveness to cisplatin in terms of
J Pathol 2009; 219: 491–500 DOI: 10.1002/path
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both decreased cell viability and increased expression
of apoptotic markers. Conversely, overexpression of
seladin-1 induced a higher survival rate and a clear
anti-apoptotic effect.
In conclusion, the present study shows for the first
time that the seladin-1 gene is highly expressed in
specific histological elements of non-seminomatous
TGCTs compared with seminoma and this may
account for differences in the propensity of TGCTs
to undergo apoptosis following anti-tumoural therapy.
The experiments performed on NT2 cells clearly show
that this protein interferes with the apoptotic response
to cisplatin treatment through the inhibition of caspase-
3 activation. In view of these results, further studies
on chemoresistant cell lines and tumours should reveal
whether seladin-1 might be targeted to develop phar-
macological strategies to enforce caspase-3 activation
and thus to improve further the therapeutic outcome
of testis cancer.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article.
Figure S1. Expression level before and after differentiation with retinoic acid of (a) γ enolase, (b) OCT4,
and (c) NANOG.
Figure S2. MTS-tetrazolium salt assay in NT2 cells 24–48 h after treatment with cisplatin.
Figure S3. Real-time RT-PCR quantification of the seladin-1 transcript in undifferentiated and differen-
tiated NT2 cells 48 h after treatment with cisplatin.
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